



MARKET FUNDAMENTALS



ECONOMIC INDICATORS



Sources:
Federal Statistical Office, ECB, Bundesbank

TRANSACTION VOLUME

The German healthcare real estate market performed very dynamically in H1 2026. Transaction volume amounted to around €1.82 billion, more than doubling compared with the same period of the previous year. At the same time, after just six months, the full-year 2025 volume of €1.22 billion was exceeded by around 50%. Around €592 million was attributable to Q2, more than three times the level recorded in the same quarter of the previous year. The quarter was significantly shaped by a large-volume, nationwide portfolio transaction in the stationary medical care segment. Overall, around €86 million was attributable to nursing care properties in Q2, of which €57 million related to nursing homes and €29 million to assisted living. Medical care properties reached a volume of around €506 million, of which €444 million was attributable to stationary medical care and €62 million to ambulatory medical care. Demand from institutional investors remains high and is focused particularly on crisis-resilient uses with stable, demographically supported income models. While large-volume portfolios supported market activity, assisted living remained below the transactionally strong prior-year level due to limited product availability and a lack of new-build activity.


PRIME YIELDS

Prime yields for healthcare properties also remained stable in Q2 2026. Nursing homes continued to stand at 5.10%, assisted living at 4.50%. Prime yields for ambulatory medical care properties stood at 4.75%, while stationary medical care properties stood at 5.75%. Given the high level of demand and limited product availability, a stable yield environment is also expected over the remainder of the year.


SELECTED HEALTHCARE TRANSACTIONS 2026

Property / Address	Quarter	City	Seller / Buyer	Purchase Price (€ m)
Cofinimmo takeover (79%) – nursing home portfolio	Q1	Multiple	Cofinimmo / Aedifica	~ 755
Vitality Portfolio, MEDICLIN rehabilitation clinics	Q2	Multiple	Patrizia / K2MB	confidential
Medical centre portfolio	Q1	Multiple	Northwest Healthcare / TPG	~ 220


TRANSACTION VOLUME



PRIME YIELDS BY PROPERTY TYPE



TRANSACTION VOLUME Q1-2 2026



OUTLOOK

- Cushman & Wakefield expects investment momentum to remain high in H2 2026, particularly for large-volume portfolios and ambulatory care concepts.
- The Hospital Reform Adjustment Act and the Hospital Transformation Fund are providing additional planning certainty.
- If the current momentum continues, 2026 could become one of the stronger years for the German healthcare real estate market.

EXPLANATION OF TERMS

Healthcare Transaction Volume: Total purchase price of all traded healthcare properties. This includes nursing homes, assisted living properties, as well as properties for ambulatory and stationary medical care.

Prime Yield: Represents the lowest net initial yield achievable for a prime property in a prime location, based on current market evidence of supply, demand, and transacted prices. The property is typically let long-term to tenants with strong credit ratings.

A CUSHMAN & WAKEFIELD RESEARCH PUBLICATION

Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for occupiers and investors with approximately 53,000 employees in over 350 offices and nearly 60 countries. In 2025, the firm reported revenue of \$10.3 billion across its core service lines of Services, Leasing, Capital markets, and Valuation and other. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com.

JAN-BASTIAN KNOD
Head of Residential Investment
Germany & Healthcare Advisory
Tel: +49 69 50 60 73 261
jan-bastian.knod@cushwake.com

MARTIN POLIFKE
Head of Business Development
Services Germany
Tel: +49 69 50 60 73 026
martin.polifke@cushwake.com

ROBERT SCHMIDT
Associate Director
Research Germany
Tel: +49 30 726 218 280
robert.schmidt@cushwake.com

©2026 Cushman & Wakefield. All rights reserved.
This report is issued on a specific date and will be prepared only for the purpose stated . This report is further compiled from information obtained from sources which C&W has rigorously checked and believes to be reliable upon the time of issuance, however C&W has not verified such information and cannot guarantee that it is accurate or complete. No warranty or representation, express or implied, is made as to the accuracy or completeness of any of the information contained in this report compiled from third parties and C&W shall not be liable to any reader of this report or any third party in any way whatsoever. All expressions of opinion are subject to change. The prior written consent of C&W is required before this report or any excerpts thereof are mentioned in any document, offering circular, publication or official statement of disclose.